

S1 Table. Dose modification and 10 years outcomes in KSPNO M051 and S081

	10-Year PFS (%)^{a)}	95% CI (%)	p-value	10-Year DSS (%)^{a)}	95% CI (%)	p-value	10-Year OS (%)^{a)}	95% CI (%)	p-value
KSPNO			0.03			0.04			0.23
M051 with SR^{b)}									
> 80% (n=16)	100	-		100	-		93.8	82.6-100	
≤ 80% (n=7)	68.6	40.3-100		60.0	29.3-100		60.0	29.3-100	
KSPNO									
S081 with HR^{c)}									
chemotherapy			0.24			0.29			0.27
> 80% (n=23)	65.3	47.3-90.2		65.2	45.5-93.2		56.3	37.9-83.5	
≤ 80% (n=10)	90.0	73.2-100		90.0	73.2-100		80.0	58.7-100	
HDC^{d)}			0.5			0.66			0.77
> 80% (n=15)	76.4	56.0-100		75.0	54.1-100		60.0	39.7-90.7	
≤ 80% (n=15)	61.1	38.2-97.8		39.3	9.6-100		35.4	8.5-100	
Total^{e)}			0.97			0.74			0.89
> 80% (n=19)	68.8	49.1-96.4		69.5	48.0-100		57.9	37.9-88.5	
≤ 80% (n=11)	72.7	50.6-100		72.7	50.6-100		63.6	40.7-99.5	

CI, confidence interval; DSS, disease-specific survival; HDC, high-dose chemotherapy; HR, high-risk; KSPNO, Korean Society of Pediatric Neuro-Oncology; OS, overall survival; PFS, progression-free survival; SR, standard risk. ^{a)}Kaplan-Meier estimator with log-rank test, ^{b)}Patients in the SR, treated with KSPNO M051 regimen, ^{c)}Patients in the HR, treated with KSPNO S081 regimen, ^{d)}Patients treated with tandem HDC with autologous stem cell rescue, ^{e)}Dose considering the total of chemotherapy and HDC.